- Firefly Neuroscience (AIFF, Financial) achieved ~87% accuracy in differentiating Alzheimer's stages using combined EEG and vMRI technology.
- The research highlights the potential of EEG/ERP as a cost-effective, less invasive diagnostic tool.
- A proprietary database of over 180,000 standardized EEG/ERP records was utilized.
Firefly Neuroscience (NASDAQ: AIFF) has reported a significant advancement in Alzheimer's research by developing a new method to distinguish between subjective cognitive decline (SCD), mild cognitive impairment (MCI), and dementia. This approach utilizes a combination of electroencephalography/event-related potentials (EEG/ERP) and volumetric MRI (vMRI), achieving approximately 87% accuracy in identifying these cognitive conditions. Notably, when applying EEG measures alone, the accuracy reached around 80%.
The study, which utilized real-world data from memory clinics, involved 161 patients for EEG tests and 111 for MRI. It identified three key predictive EEG measures—reaction time, commission errors, and P300b amplitude—and underscored the significance of left temporal lobe size from the MRI as a crucial predictor of cognitive issues.
This new method builds on Firefly's FDA-cleared Brain Network Analytics (BNA™) AI platform and the recent acquisition of Evoke Neuroscience. By leveraging a comprehensive database containing over 180,000 standardized EEG/ERP records, Firefly aims to create a more accessible and scalable approach for early Alzheimer's detection and staging.
Firefly's innovative approach provides a less invasive, more cost-effective alternative to traditional testing methods, enabling broader implementation across various healthcare settings. This research marks a critical step toward objective biomarkers and early intervention in Alzheimer's disease, potentially transforming diagnostic practices and improving patient outcomes.
